Maine Medicaid spending on GLP-1 drugs

How much did Maine Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $40.6 million for GLP-1 drugs paid through Maine Medicaid in 2025, across at least 41,655 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 41 rows of 162, so these figures are floors.

Pharmacies were reimbursed at least $11.2 million for GLP-1 drugs paid through Maine Medicaid in 2026 (quarter 1 only, as posted so far), across at least 11,118 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 11 rows of 40, so these figures are floors.

By year and ingredient

2020at least $240,254No data$3,047,276$3,156,765at least $902,124SuppressedSuppressedat least $7,346,419
2021at least $643,884No data$3,398,630at least $7,906,041at least $504,203SuppressedSuppressedat least $12,452,758
2022at least $1,239,568at least $17,039$3,903,125at least $13,122,594at least $317,579SuppressedSuppressedat least $18,599,906
2023at least $2,503,237at least $1,012,217$4,616,588at least $20,017,967at least $232,224SuppressedSuppressedat least $28,382,234
2024at least $8,407,603$3,294,919at least $2,232,476at least $19,270,578at least $189,018SuppressedNo dataat least $33,394,593
2025at least $12,465,231at least $5,608,384at least $864,092at least $21,645,397at least $33,028No dataNo dataat least $40,616,132
2026 (Q1)$3,626,614$2,064,959at least $151,696at least $5,335,933No dataNo dataNo dataat least $11,179,202

By product, 2025

Ozempic$8,917,6799,1090 of 12
Rybelsusat least $2,237,794at least 2,2924 of 16
Wegovyat least $1,309,757at least 1,0021 of 20
Mounjaro$4,820,7334,5780 of 24
Zepboundat least $787,651at least 7588 of 24
Liraglutide (generic name listing)at least $206,998at least 34811 of 22
SaxendaSuppressedSuppressed3 of 3
Victoza$657,0941,0340 of 8
Trulicityat least $21,645,397at least 22,4939 of 26
Bydureonat least $33,028at least 411 of 3
ByettaSuppressedSuppressed4 of 4

By quarter, 2025

Q1 2025at least $6,792,925at least 7,11817 of 41
Q2 2025at least $11,235,854at least 11,51710 of 42
Q3 2025at least $10,788,638at least 11,0237 of 41
Q4 2025at least $11,798,716at least 11,9977 of 38

By quarter, 2026 (posted so far)

Q1 2026at least $11,179,202at least 11,11811 of 40

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.